ClinicalTrials.gg
CompletedNCT03240445KIPEVUpdated May 14, 2019

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203

A Phase 1 interventional study of ODM-203 (Period 1) and ODM-203 (Period 2) in Healthy, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This Phase I study in healthy male volunteers will evaluate the impact of the effect of food on the pharmacokinetic profile of ODM-203.

Read the detailed description

This study will be a single dose part randomised cross over study with up to 6 study periods. ODM-203 may be dosed using a variety of different conditions with respect to food depending on emerging data. The impact of changing the presentation of ODM-203 may also be assessed to determine the PK of alternative formulations and identify appropriate drug formulations for further development.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Able to speak, write and understand English
  • of 18.0-32.0
  • Weight 55-95 kg
  • Adequate method of
  • Good state of health

Exclusion criteria

Exclusion Criteria:

  • Receipt of IMP in a clinical research study or donation/loss of >400ml blood within previous 3 months or previously enrolled in this study
  • History of drug or alcohol abuse or positive drugs of abuse test or regular alcohol consumption or current smoker/user of nicotine replacement products
  • Positive drugs of abuse test
  • Positive , or results
  • Donation/loss of >400ml blood within previous 3 months
  • Poor compliance or inability to follow protocol requirements/instructions/restrictions.
  • Vulnerable subjects
  • Evidence of disease of any body system including relevant psychiatric disorders or conditions requiring regular concomitant medication
  • History of significant , anaphylaxis, intolerance to drugs/food
  • Propensity to get headaches when refraining from caffeine containing beverages
  • Any abnormal laboratory value, vital signs, parameter or physical examination interfering with the test results or causing a health risk for the subject or failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Period 1

    ODM-203 dosed after food

    Drug: ODM-203 (Period 1)

  • Experimental
    Period 2

    ODM-203 dosed before food

    Drug: ODM-203 (Period 2)

  • Experimental
    Periods 3-6

    ODM-203 dosed as a tablet or dispersion

    Drug: ODM-203 (Periods 3-6)

Interventions

  • DrugODM-203 (Period 1)

    ODM-203 400mg as tablets taken 30 minutes after food

  • DrugODM-203 (Period 2)

    ODM-203 400mg as tablets taken 1 hour before a light breakfast

  • DrugODM-203 (Periods 3-6)

    ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration curve(AUC) ODM-203 in the presence and absence of food

    Area under the plasma concentration curve (AUC) will be measured to investigate the pharmacokinetic profile of ODM-203 in the presence and absence of food

    Time frame: 0 to 72 hours

Secondary outcomes

  1. Number of adverse events

    Number of adverse events counts

    Time frame: From the date of informed consent to the date of the end of study estimated to be up to 17 weeks

  2. Area under the plasma concentration curve(AUC) ORM-21444 in the presence and absence of food

    Area under the plasma concentration curve (AUC) will be measured to investigate the pharmacokinetic profile of ORM-21444 in the presence and absence of food

    Time frame: 0 to 72 hours

07

Study locations

1 site
  • Quotient Clinical Ltd
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Oct 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Aug 7, 2017
StartActual
Aug 24, 2017
Primary completionActual
Oct 23, 2017
CompletionActual
Oct 23, 2017
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03240445
Collaborators
Quotient Clinical
Responsible party
Sponsor
First posted
Aug 7, 2017
Start date
Aug 24, 2017
Primary completion
Oct 23, 2017
Completion
Oct 23, 2017
Last update
May 14, 2019

Study contacts

Clare Preskey, BSc
study director · Quotient Clinical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion